Diagnamed has signed an exclusive global license agreement with KU Center for Technology Commercialization at the University of Kansas, US, to develop the new virtual reality (VR) and artificial intelligence (AI) neurodiagnostic system (VR/AI Neuro).

The agreement also involves the commercialisation of VR/AI Neuro’s intellectual property.

The VR/AI Neuro system is designed for assessing, diagnosing and monitoring neurodegenerative diseases, including Parkinson’s disease.

It aims to enable clinical and remote neurological diagnosis on a low-cost device.

The system is a portable VR device that can connect with a physician remotely and show patients’ eye movements in videos.

This helps provide more accurate diagnoses, with physicians spending less time on making a correct diagnosis and patients spending less on transportation costs.

DiagnaMed stated that the VR/AI Neuro system complements and strengthens its proposed complete-spectrum digital diagnostics brain health solutions, which include BRAIN AGE and BrainTremor.

BRAIN AGE is an electroencephalogram-based (EEG) AI solution intended for detecting the brain age of an individual for clinical and home use.

BrainTremor is a wearable device that can detect tremors caused by Parkinson’s disease as well as essential tremors.

DiagnaMed Board chairman Fabio Chianelli said: “We are excited to advance the development of a novel virtual reality and artificial intelligence neurodiagnostic system that will aim to change the way neurodegenerative diseases are diagnosed and managed.

“We are focused on developing and commercialising next-generation digital diagnostic tools for brain health in mental health and neurological disorders.

“The VR/AI Neuro system complements our product development programmes, including BRAIN AGE and BrainTremor, to ensure a full suite of evaluation solutions for healthcare providers to manage their patient’s conditions effectively.”